NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy
Updated: May 23, 2022
NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy
MGUS
Rifaximin in Patients With Monoclonal Gammopathy
This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.
IgA Monoclonal Gammopathy
IgG Monoclonal Gammopathy
IgM Monoclonal Gammopathy
Light Chain Deposition Disease
Monoclonal Gammopathy
Smoldering Waldenstrom Macroglobulinemia
Waldenstrom Macroglobulinemia
Gammopathy, Monoclonal
Gammopathy Igg
Sponsor
Emory University
Collaborator
The Leukemia and Lymphoma Society
Location
United States, Georgia
ClinicalTrials.gov Identifier: NCT03820817
Official Title: Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy
First Posted : January 29, 2019
Drug: Rifaximin
Location
United States, Georgia